Showing results (81-90 of 115) with videos related to
Sort By:
Pageof 12
Frontiers in Oncology|April 7, 2022
Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTDSebastian Stasik, Michael Kramer, Sven Zukunft, et al.Blood Advances|September 18, 2024
Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AMLJulia M Unglaub, Richard F Schlenk, Jan Moritz Middeke, et al.Experimental Hematology|June 15, 2015
MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AMLTim Sauer, Maria Francisca Arteaga, Fabienne Isken, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALLMatthias Stelljes, Simon Raffel, Nael Alakel, et al.Plos One|November 18, 2017
Resting-state fMRI in sleeping infants more closely resembles adult sleep than adult wakefulnessAnish Mitra, Abraham Z Snyder, Enzo Tagliazucchi, et al.Oncoimmunology|June 16, 2025
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastomaAlexandros Kourtesakis, Eileen Bailey, Hiu Nam Hannah Chow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.Cancer Discovery|March 9, 2023
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/VenetoclaxAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.Cancer Discovery|October 19, 2022
A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid LeukemiaFengbiao Zhou, Nesrine Aroua, Yi Liu, et al.Trials|September 15, 2023
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITDSonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, et al.Pageof 12